Roni Mamluk Ph.D.
Net Worth
Last updated:
What is Roni Mamluk Ph.D. net worth?
The estimated net worth of Dr. Roni Mamluk Ph.D. is at least $2,730,320 as of 24 Feb 2021. He has earned $187,920 from insider trading and has received compensation worth at least $2,542,400 in Ayala Pharmaceuticals, Inc..
What is the salary of Roni Mamluk Ph.D.?
Dr. Roni Mamluk Ph.D. salary is $635,600 per year as Pres, Chief Executive Officer & Director in Ayala Pharmaceuticals, Inc..
How old is Roni Mamluk Ph.D.?
Dr. Roni Mamluk Ph.D. is 58 years old, born in 1967.
What stocks does Roni Mamluk Ph.D. currently own?
As insider, Dr. Roni Mamluk Ph.D. owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| Ayala Pharmaceuticals, Inc. (AYLA) | Pres, Chief Executive Officer & Director | 145,345 | $0 | $0 |
What does Ayala Pharmaceuticals, Inc. do?
Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, focuses on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers. The company's lead product candidate is AL101, a potent, selective, and injectable small molecule gamma secretase inhibitor (GSI) that is in Phase II clinical trial for the treatment of recurrent/metastatic adenoid cystic carcinoma for patients bearing Notch-activating mutations. It is also involved in developing AL102, a potent, selective, and oral small molecule GSI that is in Phase II/III pivotal study for the treatment of desmoid tumors. Ayala Pharmaceuticals, Inc. has a collaboration agreement with Novartis International Pharmaceutical Limited to develop AL102 for the treatment of multiple myeloma. The company was incorporated in 2017 and is headquartered in Rehovot, Israel.
Roni Mamluk Ph.D. insider trading
Ayala Pharmaceuticals, Inc.
Dr. Roni Mamluk Ph.D. has made 5 insider trades in 2021, according to the Form 4 filled with the SEC. Most recently he sold 10,800 units of AYLA stock worth $187,920 on 24 Feb 2021.
The largest trade he's ever made was exercising 19,466 units of AYLA stock on 20 Jan 2021. As of 24 Feb 2021 he still owns at least 145,345 units of AYLA stock.
Ayala Pharmaceuticals key executives
Ayala Pharmaceuticals, Inc. executives and other stock owners filed with the SEC:
- Dr. Gary B. Gordon M.D., Ph.D. (72) Chief Medical Officer
- Dr. Roni Mamluk Ph.D. (58) Pres, Chief Executive Officer & Director
- Mr. Yossi Maimon CPA, M.B.A., CPA, MBA (54) Chief Financial Officer, Sec. & Treasurer